Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 50,000 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) CEO Patrick Miles sold 50,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total transaction of $601,500.00. Following the transaction, the chief executive officer now owns 6,152,544 shares in the company, valued at $74,015,104.32. This represents a 0.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Patrick Miles also recently made the following trade(s):

• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00.

Alphatec Stock Up 5.9 %

NASDAQ:ATEC traded up $0.68 during trading hours on Tuesday, reaching $12.14. The company's stock had a trading volume of 1,708,866 shares, compared to its average volume of 1,842,925. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $17.34. The business's 50-day moving average is $10.15 and its 200-day moving average is $8.07. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -9.48 and a beta of 1.43.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in Alphatec by 119.3% during the fourth quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company's stock worth $6,079,000 after purchasing an additional 360,258 shares during the period. Olympiad Research LP bought a new stake in shares of Alphatec during the 4th quarter worth $160,000. Ieq Capital LLC bought a new position in Alphatec in the 4th quarter worth $323,000. New York State Common Retirement Fund lifted its position in Alphatec by 21.2% during the 4th quarter. New York State Common Retirement Fund now owns 1,202,334 shares of the medical technology company's stock worth $11,037,000 after acquiring an additional 210,519 shares during the last quarter. Finally, Congress Asset Management Co. boosted its holdings in Alphatec by 235.4% during the fourth quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company's stock valued at $3,993,000 after acquiring an additional 305,296 shares during the period. Institutional investors and hedge funds own 66.35% of the company's stock.

Analyst Upgrades and Downgrades

ATEC has been the topic of several recent research reports. Needham & Company LLC lifted their price target on shares of Alphatec from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. Barclays boosted their target price on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $17.56.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.